Resources Contact Us Home
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Image Number 13 for United States Patent #8119616.

The present invention relates to a composition comprising an inclusion complex of a cyclodextrin and quinazoline containing zinc-binding moiety based derivatives. The cyclodextrin is preferable a .beta.-cyclodextrin or a derivative thereof. The quinazolines have enhanced and unexpected properties as inhibitors of epidermal growth factor receptor tyrosine kinase (EGFR-TK) and their use in the treatment of EGFR-TK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

  Recently Added Patents
Secure data exchange between data processing systems
Selected alert delivery in a distributed processing system
Methods and apparatus for voltage selection for a MOSFET switch device
Immunotherapy in cancer treatment
Method for manufacturing photoelectric conversion device
Switch redundancy in systems with dual-star backplanes
Protective vest
  Randomly Featured Patents
Modified epoxy resin modified epoxy resin composition and a process for the preparation of the modified epoxy resin
Plasma display panel apparatus performing image display drive using display method that includes write period and sustain period, and driving method for the same
Routing extensions for telecommunication network system and method
Load anticipating engine/transmission control system
Advertising simulated neon sign display
Process for the preparation of 4'-deoxy-daunorubicin and 4'-deoxy-doxorubicin
Diagnostic apparatus for use in an exhaust system of an internal combustion engine
Communication method of contactless ID card and integrated circuit used in communication method
Doll and pillow carrying case
Liquid crystal display and biaxial compensation film